Cancer Research Technology Secure Orphan Drug Designation for Fenretinide on Behalf of Cancer Research UK

London, UK 27 February 2007 – Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, today announce that Cancer Research UK has received orphan drug designation for use of fenretinide in the treatment of Ewing’s Sarcoma Family of Tumours from the Food and Drug Administration (FDA) and for the treatment of soft tissue sarcomas and malignant bone tumours from the European Commission.